Today's story
Acadia expects Rett drug protection through 2041
Trofinetide U.S. protection expected through March 28, 2041—nearly five years past the July 2036 method-of-use patent—after USPTO allowance for weight-banded dosing.
Health · 7 sources · 4dRead itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Rett syndrome
Rett syndrome (RTT) is a genetic disorder that typically becomes apparent after 6–18 months of age and almost exclusively in girls. Symptoms include impairments in language and coordination, and repetitive movements. Those affected often have slower growth, difficulty walking, and a smaller head size. Complications of Rett syndrome can include seizures, scoliosis, and sleeping problems. The severity of the condition is variable.
Everything about Rett syndrome →